CN111393677A - Preparation method of nano composite hydrogel for rapid blood coagulation promotion - Google Patents
Preparation method of nano composite hydrogel for rapid blood coagulation promotion Download PDFInfo
- Publication number
- CN111393677A CN111393677A CN202010353209.1A CN202010353209A CN111393677A CN 111393677 A CN111393677 A CN 111393677A CN 202010353209 A CN202010353209 A CN 202010353209A CN 111393677 A CN111393677 A CN 111393677A
- Authority
- CN
- China
- Prior art keywords
- blood coagulation
- hydrogel
- blood
- preparing
- rapidly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 30
- 230000023555 blood coagulation Effects 0.000 title claims abstract description 29
- 239000002114 nanocomposite Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 21
- 230000005855 radiation Effects 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 238000010894 electron beam technology Methods 0.000 claims abstract description 13
- 239000000701 coagulant Substances 0.000 claims abstract description 12
- 238000004132 cross linking Methods 0.000 claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 239000011521 glass Substances 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000008014 freezing Effects 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 108090000190 Thrombin Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003805 procoagulant Substances 0.000 claims description 6
- 229960004072 thrombin Drugs 0.000 claims description 6
- 239000003463 adsorbent Substances 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 5
- -1 polydimethylsiloxane Polymers 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 4
- 108010039627 Aprotinin Proteins 0.000 claims description 4
- 229960002684 aminocaproic acid Drugs 0.000 claims description 4
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 4
- 229960004405 aprotinin Drugs 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 238000003892 spreading Methods 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 4
- 229960000401 tranexamic acid Drugs 0.000 claims description 4
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 claims description 4
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000006229 carbon black Substances 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000010453 quartz Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229910052681 coesite Inorganic materials 0.000 claims description 2
- 229910052906 cristobalite Inorganic materials 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 229910052682 stishovite Inorganic materials 0.000 claims description 2
- 229910052905 tridymite Inorganic materials 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 238000005345 coagulation Methods 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000015271 coagulation Effects 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 4
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 230000035931 haemagglutination Effects 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- IXAZNYYEGLSHOS-UHFFFAOYSA-N 2-aminoethanol;phosphoric acid Chemical compound NCCO.OP(O)(O)=O IXAZNYYEGLSHOS-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002558 medical inspection Methods 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005285 chemical preparation method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2301/08—Cellulose derivatives
- C08J2301/26—Cellulose ethers
- C08J2301/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2401/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2401/08—Cellulose derivatives
- C08J2401/26—Cellulose ethers
- C08J2401/28—Alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2403/00—Characterised by the use of starch, amylose or amylopectin or of their derivatives or degradation products
- C08J2403/02—Starch; Degradation products thereof, e.g. dextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a preparation method of a nano composite hydrogel for rapid blood coagulation promotion, belonging to the technical field of medical auxiliary materials. The blood coagulant which can be applied to the vacuum blood collection tube is prepared by utilizing an electron beam radiation crosslinking technology to carry out radiation crosslinking reaction on natural polysaccharide, blood coagulation factors and the like. The method has the advantages of capability of shortening the hemagglutination and coagulation time, no influence on biochemical detection indexes, no toxicity, mild reaction conditions, no addition of a cross-linking agent in the reaction process, easy storage and the like.
Description
Technical Field
The invention belongs to the technical field of medical auxiliary materials, and relates to a preparation method of a nano composite hydrogel for rapid blood coagulation promotion.
Background
The medical inspection technology is now in the new era of full automation and microcomputer management, and is in the field of clinical inspection, no matter in clinical chemistry, serology, immunology and other detection. Most of the samples used require serum isolation. How to separate serum rapidly and sufficiently and simplify the operation is a problem which needs to be solved urgently by the medical inspection community. In addition, most clinical indexes such as biochemistry, immunity and the like use serum samples, while an isolated blood sample generally needs about 1 hour from coagulation to serum exudation, and the serum sample is a precondition for improving the inspection efficiency and accuracy in order to quickly obtain high-quality serum. The effective application of the rapid blood coagulant in the vacuum blood collection tube can effectively shorten the blood coagulation time, improve the serum separation efficiency and rapidly and accurately obtain the relevant results of biochemical test and immunoassay.
Chinese patent No. 104101522A describes a composite blood coagulation promoting powder composed of coagulant, adsorbent, stabilizer, fixative, blood cell wall removing agent, and anti-fibrinolytic agent, which can be used in vacuum blood collection tubes or other non-vacuum blood collection tubes by using alcohol, isopropanol, water, etc. as solvent to prepare suspension. The patent technology has the characteristics of good procoagulant effect, easy storage, low-temperature hemolysis prevention and the like. However, the thrombin component described in this patent is thrombin, and thus, a special apparatus is required for the detection, which is disadvantageous in that the cost investment is high. Further, chinese patent 102212514a describes a blood coagulant for blood collection containers, which is characterized in that the blood coagulant is composed of a blood adhesion preventing agent, thrombin, phosphatidylethanolamine, fine silica powder and ethanol, and can be used in vacuum blood collection tubes or other non-vacuum blood collection tubes. The phosphatidylethanolamine and the silicon dioxide micropowder which are described in the patent are used together, so that blood coagulation can be promoted, fibrin filaments can be avoided, the sample storage time is long, the blood coagulation speed is slightly influenced by temperature, and the biochemical and immune experiment detection indexes including ions are not influenced. In addition, the blood sampling tube is not influenced by the material of the blood sampling tube, and no hemolysis phenomenon is caused by the glass tube or the plastic tube. The longest blood coagulation time is the biggest defect of the patent.
A hydrogel is a three-dimensional or interpenetrating network between a liquid and a solid, a hydrophilic polymer gel that swells significantly in water, but is insoluble in water. The invention utilizes radiation technology to effectively compound the nano coagulation promoting factor and the hydrogel carrier, and utilizes the strong water absorbability of the dry powder particles to enhance the effect of the nano coagulation promoting factor on blood coagulation. This vacuum test tube makes the blood of gathering solidify in 3 minutes, does not arouse the hemolysis, stops fibrin silk's formation, need not special check out test set, and the material of vacuum test tube does not influence the hemolysis, easily stores, is expected to be applied to vacuum test tube and is managed or non-vacuum test tube.
Compared with a chemical preparation method, the radiation technology realizes effective supplement and perfection, and the specific expression is that no substance toxic to human bodies is required to be added in the ① reaction process, the crosslinking degree is high, the hydrogel purity is high, the reaction condition ② is mild and can be carried out at room temperature, ③ can accurately regulate and control the microstructure and the water absorption performance of the hydrogel by controlling the polymer components and the radiation condition, the preparation, shaping and sterilization processes of the ④ hydrogel can be synchronously completed, and the economic cost for preparing the hydrogel by using the radiation technology is lower in comprehensive and long-term view.
The invention aims to solve the problem of disclosing a preparation method of a nano composite hydrogel for rapidly accelerating blood coagulation so as to overcome the defects in the prior art.
Disclosure of Invention
The invention aims to provide a preparation method of a nano composite hydrogel for rapidly accelerating blood coagulation aiming at the problems in the prior art, and the technical problem to be solved by the invention is how to prepare a hydrogel-based blood coagulation accelerator by taking natural polysaccharide as a main raw material.
The purpose of the invention can be realized by the following technical scheme: the preparation method of the nano composite hydrogel for rapidly accelerating blood coagulation is characterized by comprising the following steps:
① mixing 0.01-1 g coagulant, 7-100 g adsorbent, 0.15-5 g blood cell wall removing agent and 0.15-5 g anti-fibrinolytic agent uniformly, drying at a temperature not exceeding 100 ℃;
② preparing natural polysaccharide into water solution, stirring for 0.5-2 h to form uniform polymer solution;
③ dispersing the coagulant powder dispersion system obtained in step ① into the natural polysaccharide solution obtained in step ②, spreading the mixed solution in a glass dish to a thickness of 2-4 mm, rapidly and circularly freezing and thawing for 3-5 times, and storing in a 4 deg.C freezer for use;
④, placing the sample obtained in the step ③ under an electron beam for radiation crosslinking reaction, wherein the selected electron beam energy is 1-5 MeV, the radiation dose is 4-40 kGy, the dose rate is 4-20 kGy/pass, and the final product is the rapid blood coagulation promoting nanocomposite hydrogel.
The natural polysaccharide is one or more of chitosan and derivatives thereof, cellulose and derivatives thereof, sodium alginate and the like. One or more natural polysaccharides can be subjected to self-crosslinking or mutual crosslinking in the irradiation process, so that the hydrogel is ensured to have a certain network structure, and the water absorption performance of the hydrogel is further enhanced.
The coagulant is one or more of thrombin, phosphate ethanolamine, wedelolactone and the like.
The adsorbent is calcium carbonate, quartz powder, white carbon black, talcum powder and SiO2And the like.
The blood cell wall removing agent is one or more of glycine, polydimethylsiloxane, tween 80 and the like.
The fibrinolytic agent is one or more of tranexamic acid, aminocaproic acid, aprotinin and the like.
The beneficial effects are that:
1. the radiation technology is non-toxic, the reaction condition is mild, no cross-linking agent, initiator and any substance toxic to human bodies are added in the reaction process, and secondary pollution can be effectively avoided.
2. The rapid coagulation of blood is realized, the hemolysis phenomenon and the formation of fibrin filaments are avoided, the high-quality separation efficiency of large-volume serum can be realized, and the rapid coagulation accelerating effect of blood is good.
3. The nano composite hydrogel product for accelerating blood coagulation quickly appears as powder and is easy to transport and store.
4. The effective preparation of the compound solvent preparation is beneficial to production and cost saving.
5. The coagulant can be prepared into suspension with water, ethanol and the like according to a certain proportion, sprayed on the wall of a vacuum blood collection vessel, can directly act with blood, shortens the blood coagulation time, and does not influence biochemical detection indexes.
6. The product can solidify the collected blood within 3 minutes, does not need special inspection equipment, does not influence hemolysis by the material of the used vacuum blood collection tube, is easy to store, and is particularly suitable for the clinical treatment fields of rapid high-quality biochemical inspection, immune inspection and the like.
Detailed Description
The following are specific examples of the present invention and further describe the technical solutions of the present invention, but the present invention is not limited to these examples.
Example 1:
phosphate Ethanolamine (0.01g), 30nm SiO was weighed2(7g) Uniformly mixing polydimethylsiloxane (0.15g) and tranexamic acid (0.15g), dissolving the mixture in an ethanol solution of 50m L, filtering and drying to obtain the blood coagulation promoting powder, doping the blood coagulation promoting powder into an ethanol solution of carboxymethyl chitosan and sodium alginate (1:4) according to the mass fraction of 2%, paving the mixture in a glass dish of 90mm, wherein the thickness is about 2-4 mm, quickly and circularly freezing and unfreezing the mixture for 3-5 times, storing the mixture in a freezer at 4 ℃ for later use, placing an obtained sample under an electron beam for radiation crosslinking reaction, selecting the electron beam energy of 1MeV, the radiation dose of 4kGy and the dose rate of 4kGy/pass, and finally obtaining the product, namely the blood rapidly-procoagulated nano composite hydrogelHemolysis and fibrin thread formation.
Example 2:
weighing 0.1g of wedelolactone, 10g of white carbon black, 800.2g of tween and 0.15g of aminocaproic acid, uniformly mixing, dissolving in a water solution of 50m L, filtering and drying to obtain blood coagulation promoting powder, doping the blood coagulation promoting powder into a carboxymethyl chitosan and carboxymethyl cellulose (1:3) water solution according to the mass fraction of 2%, paving the mixture into a 90mm glass dish to obtain a glass dish with the thickness of about 2-4 mm, quickly and circularly freezing and unfreezing for 3-5 times, storing the glass dish in a freezer at 4 ℃ for later use, placing an obtained sample in an electron beam for radiation crosslinking reaction, selecting the electron beam energy of 1MeV, the radiation dose of 20kGy and the dose rate of 10kGy/pass, and finally obtaining the product, namely the quick-coagulation promoting nano hydrogel.
Example 3:
weighing 0.5g of thrombin, 50g of calcium carbonate, 2.5g of glycine and 2.5g of aminocaproic acid, uniformly mixing, dissolving in 50m L ethanol solution, filtering and drying to obtain the blood coagulation promoting powder, doping the blood coagulation promoting powder into the ethanol solution of carboxymethyl cellulose and sodium alginate (1:2) according to the mass fraction of 2%, paving the mixture into a 90mm glass dish, quickly and circularly freezing and unfreezing for 3-5 times at the thickness of about 2-4 mm, and storing the glass dish in a freezing cabinet at 4 ℃ for later use.
Example 4:
weighing 0.8g of phosphate ethanolamine and wedelolactone (1:1) in total, 80g of talcum powder, 3g of polydimethylsiloxane and 3g of aprotinin, uniformly mixing, dissolving in 50m L ethanol solution, filtering and drying to obtain blood procoagulant powder, doping the powder into starch and carboxymethyl chitosan (1:3) hydrogel solution according to the mass fraction of 2%, spreading the solution into a 90mm glass dish, quickly and circularly freezing and thawing for 3-5 times at the thickness of 2-4 mm, and storing in a 4 ℃ freezer for later use, placing a sample obtained in the step ③ in an electron beam for radiation crosslinking reaction, wherein the selected electron beam energy is 1MeV, the radiation dose is 40kGy, the dose rate is 10kGy/pass, and the finally obtained product is the quick procoagulant nano hydrogel.
Example 5:
weighing 1g of phosphoethanolamine, 100g of quartz powder, 5g of dimethyl siloxane, Tween 80(1:1), 5g of tranexamic acid and aprotinin (1:1), uniformly mixing, dissolving in 50m L ethanol solution, filtering and drying to obtain the blood procoagulant powder, doping the blood procoagulant powder into carboxymethyl chitosan and carrageenan (1:1) hydrogel solution according to the mass fraction of 2%, spreading the mixture to a 90mm glass dish, quickly circulating and freezing and thawing for 3-5 times with the thickness of about 2-4 mm, placing the glass dish in a freezer at 4 ℃ for storage, placing the sample obtained in the step ③ under an electron beam for radiation crosslinking reaction, selecting the electron beam energy of 1MeV, the radiation dose of 40kGy and the dose rate of 20kGy/pass, and finally obtaining the product, namely the quick procoagulant nano hydrogel.
The specific embodiments described herein are merely illustrative of the spirit of the invention. Various modifications or additions may be made to the described embodiments or alternatives may be employed by those skilled in the art without departing from the spirit or ambit of the invention as defined in the appended claims.
Claims (6)
1. The preparation method of the nano composite hydrogel for rapidly accelerating blood coagulation is characterized by comprising the following steps:
① mixing 0.01-1 g coagulant, 7-100 g adsorbent, 0.15-5 g blood cell wall removing agent and 0.15-5 g anti-fibrinolytic agent uniformly, drying at a temperature not exceeding 100 ℃;
② preparing natural polysaccharide into water solution, stirring for 0.5-2 h to form uniform polymer solution;
③ dispersing the coagulant powder dispersion system obtained in step ① into the natural polysaccharide solution obtained in step ②, spreading the mixed solution in a glass dish to a thickness of 2-4 mm, rapidly and circularly freezing and thawing for 3-5 times, and storing in a 4 deg.C freezer for use;
④, placing the sample obtained in the step ③ under an electron beam for radiation crosslinking reaction, wherein the selected electron beam energy is 1-5 MeV, the radiation dose is 4-40 kGy, the dose rate is 4-20 kGy/pass, and the final product is the rapid blood coagulation promoting nanocomposite hydrogel.
2. The method for preparing the nanocomposite hydrogel for rapidly accelerating blood coagulation according to claim 1, wherein the natural polysaccharide is one or more of chitosan and derivatives thereof, cellulose and derivatives thereof, sodium alginate and the like.
3. The method for preparing the nanocomposite hydrogel for rapidly accelerating blood coagulation according to claim 1 or 2, wherein the coagulant is one or more of thrombin, phosphate wedelolactone, deltoid lactone and the like.
4. The method for preparing the nano-composite hydrogel for rapidly accelerating blood coagulation according to claim 3, wherein the adsorbent is calcium carbonate, quartz powder, white carbon black, talcum powder or SiO2And the like.
5. The method for preparing the nanocomposite hydrogel for rapidly procoagulant blood according to claim 3, wherein the blood cell wall removing agent is one or more of glycine, polydimethylsiloxane, Tween 80 and the like.
6. The method for preparing the nanocomposite hydrogel for rapidly accelerating blood coagulation according to claim 3, wherein the anti-fibrinolytic agent is one or more of tranexamic acid, aminocaproic acid, aprotinin and the like.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010353209.1A CN111393677A (en) | 2020-04-29 | 2020-04-29 | Preparation method of nano composite hydrogel for rapid blood coagulation promotion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010353209.1A CN111393677A (en) | 2020-04-29 | 2020-04-29 | Preparation method of nano composite hydrogel for rapid blood coagulation promotion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111393677A true CN111393677A (en) | 2020-07-10 |
Family
ID=71425534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010353209.1A Pending CN111393677A (en) | 2020-04-29 | 2020-04-29 | Preparation method of nano composite hydrogel for rapid blood coagulation promotion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111393677A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101137902A (en) * | 2005-03-17 | 2008-03-05 | 积水化学工业株式会社 | Blood coagulation accelerator and vessel for blood test |
| CN102212514A (en) * | 2011-06-17 | 2011-10-12 | 上海科华检验医学产品有限公司 | Blood coagulant for blood collection container |
| CN102451466A (en) * | 2010-11-01 | 2012-05-16 | 梁慧 | Composite high-speed coagulant and preparation method thereof |
| CN104101522A (en) * | 2013-04-10 | 2014-10-15 | 付士明 | Composite efficient blood coagulation promoting powder |
| CN104189941A (en) * | 2014-09-03 | 2014-12-10 | 北京化工大学 | Chitosan gel haemostatic material and preparation method thereof |
| CN106432810A (en) * | 2016-09-09 | 2017-02-22 | 湖北科技学院 | High-surface-tension hydrogel vitreous substitute and radiation preparation method thereof |
-
2020
- 2020-04-29 CN CN202010353209.1A patent/CN111393677A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101137902A (en) * | 2005-03-17 | 2008-03-05 | 积水化学工业株式会社 | Blood coagulation accelerator and vessel for blood test |
| CN102451466A (en) * | 2010-11-01 | 2012-05-16 | 梁慧 | Composite high-speed coagulant and preparation method thereof |
| CN102212514A (en) * | 2011-06-17 | 2011-10-12 | 上海科华检验医学产品有限公司 | Blood coagulant for blood collection container |
| CN104101522A (en) * | 2013-04-10 | 2014-10-15 | 付士明 | Composite efficient blood coagulation promoting powder |
| CN104189941A (en) * | 2014-09-03 | 2014-12-10 | 北京化工大学 | Chitosan gel haemostatic material and preparation method thereof |
| CN106432810A (en) * | 2016-09-09 | 2017-02-22 | 湖北科技学院 | High-surface-tension hydrogel vitreous substitute and radiation preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李萍等: "血液促凝剂的临床应用及评价", 《国际检验医学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210260241A1 (en) | Chitin/graphene composite sponge and preparation method and use thereof | |
| CN104511045B (en) | A kind of preparation method of the polyvinyl alcohol containing nano silver/chitosan nano fiber membrane dressing | |
| CN110343352B (en) | Double-crosslinking hydrogel based on calcium peroxide/polymer oxygen-generating particles and preparation method thereof | |
| Cai et al. | High-water-absorbing calcium alginate fibrous scaffold fabricated by microfluidic spinning for use in chronic wound dressings | |
| CN105237925A (en) | Nanometer bacterial cellulose\polyvinyl alcohol\polyethylene glycol porous composite hydrogel | |
| Li et al. | Novel SA@ Ca 2+/RCSPs core–shell structure nanofibers by electrospinning for wound dressings | |
| CN107737368B (en) | Hemostatic material and its preparation method and application | |
| CN108794771B (en) | Double-network cross-linked cellulose/silk fibroin high-strength hydrogel and preparation and application thereof | |
| CN103225126B (en) | Fibroin/sodium alginate composite nanofiber scaffold preparation method | |
| CN103087334B (en) | Method for preparing composite hydrogel of sodium alginate and artemisia desertorum seed gum | |
| CN102731801A (en) | Cross-linked sodium hyaluronate hydrogel for plastic surgery and preparation method thereof | |
| CN102940903B (en) | Method for preparing medical dressing of polysaccharide cavernous body | |
| CN104001211A (en) | Bone tissue engineering composite porous scaffold material and preparation method thereof | |
| CN108187129B (en) | Absorbable gelatin styptic powder and preparation method thereof | |
| CN111118734A (en) | Polyvinyl alcohol/carboxymethyl chitosan nanofiber medical dressing and preparation method and application thereof | |
| CN111393677A (en) | Preparation method of nano composite hydrogel for rapid blood coagulation promotion | |
| CN114702704A (en) | Functional polymer film/hydrogel film based on one-way nanopore dehydration, and preparation method and device thereof | |
| CN104018234A (en) | Preparation method of composite nanofiber membrane capable of quickly stopping bleeding | |
| CN110585122B (en) | Injectable natural triterpenoid antibacterial hydrogel and preparation method thereof | |
| Ding et al. | Enzymatically crosslinked hydrogel based on tyramine modified gelatin and sialylated chitosan | |
| CN115058028B (en) | Preparation method of polythiourethane modified sodium alginate hydrogel dressing | |
| CN104525135A (en) | Dual-gel adsorbent and production method thereof | |
| CN106496598B (en) | Aquagel of high bioactivity and preparation method thereof and purposes | |
| CN103450488A (en) | Preparation method of fibroin nano particles | |
| CN113769159A (en) | Anhydrous calcium phosphate bone cement and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200710 |